Video

Dr. Malhotra on the Rationale to Evaluate Racial Disparities in Lung Cancer Survivors

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Jyoti Malhotra, MD, MPH, medical oncologist, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Robert Wood Johnson Medical School, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Racial disparities exist throughout the treatment of patients with lung cancer, Malhotra says. These disparities are present in the setting of follow-up care and surveillance, which is a critical part of lung cancer survivorship, Malhotra explains. Follow-up care allows survivors to receive disease-related symptom management and routine screening for early detection of recurrence, Malhotra adds.

During the 2021 ASCO Annual Meeting, findings from a cross-sectional study of racial differences in follow-up care of lung cancer survivors through New Jersey’s statewide cancer registry were presented in a virtual poster. The results showed that more non-Hispanic White survivors received a surveillance scan within 1 year compared with non-Hispanic Black survivors (P = .02), Malhotra concludes.

Related Videos
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"